Kenneth Erland Johnson

Insider Reports History

Identity Names, identifiers, and filing context for this profile. 1 identity field
Reporting-owner location
Chicago, IL
SEC source record Original filing metadata and source links for verification. 1 source field
Latest reporting-owner signature
/s/ Beth Hecht, Attorney-in-Fact
Source: Latest parsed Forms 3/4/5 signature
Source evidence Original filing metadata and source links for verification. 1 source field
Transaction source note
Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for Kenneth Erland Johnson

Form 4 holding Senior Vice President, Global Development and Medical Affairs

Xeris Biopharma Holdings, Inc.

Security class
Common Stock
Shares / value
320,446
Estimated value
$1,140,788
Report date
31 Jan 2025
Price
$3.56
Ownership
Direct
Form 4 holding Sr. VP Clinical Development, Regulatory, Quality Assurance & Medical Affairs

XERIS PHARMACEUTICALS INC

Security class
Common Stock
Shares / value
0
Estimated value
Report date
05 Oct 2021
Price
Ownership
Direct
Form 4 holding Sr. VP Clinical Development, Regulatory, Quality Assurance & Medical Affairs

XERIS PHARMACEUTICALS INC

Security class
Stock Option (Right to Buy)
Shares / value
0
Estimated value
Report date
05 Oct 2021
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount

Insider Reports Filed by Kenneth Erland Johnson

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .